Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 561-571

  Tsai, Min Shao ^a,b   Weng, Shao Hsing ^a   Chen, Huang Jen ^a   Chiu, Yu Fan ^a   Huang, Yu Ching ^a   Tseng, Sheng Chieh ^a   Kuo, Ya Hsun ^a   Lin, Yun Wei ^a  

^a NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTARY 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDES AND PROTEINS; TANESPIMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DNA REPAIR; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZOQUINONES; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDONUCLEASES; ENZYME INHIBITORS; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TIME FACTORS;

EID: 84859383166     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0684     Document Type: Article

References (47)

1. Park CH, Bessho T, Matsunaga T, Sancar A. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 1995;270:22657-60.
2. de Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem 1998;273:7835-42. (Pubitemid 28168827)
3. Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J 1997;16:6559-73. (Pubitemid 27483280)
4. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993;14:2177-80. (Pubitemid 23311452)
5. Taverna P, Hansson J, Scanlon KJ, Hill BT. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis 1994;15:2053-6. (Pubitemid 24303060)
6. Zhen W, Link CJ Jr., O'Connor PM, Reed E, Parker R, Howell SB, et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992;12:3689-98.
7. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-8. (Pubitemid 24251002)
8. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91. (Pubitemid 34753602)
9. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
10. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514-21. (Pubitemid 28446331)
11. Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, et al. Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem 1996;271:29238-44. (Pubitemid 26382636)
12. Stewart DJ, Tomiak E, Shamji FM, Maziak DE, MacLeod P. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 2004;44:241-9. (Pubitemid 38482057)
13. Goksel T, Hatipoglu ON, Ozturk C, Gorguner M, Kiyik M, Yilmaz U, et al. A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer. Respirology 2005;10:456-63. (Pubitemid 43942614)
14. Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 2006;16:133-40.
15. Makin G, Dive C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Breast Cancer Res 2001;3:150-3. (Pubitemid 32390215)
16. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139. (Pubitemid 28193546)
17. Anderson SM, Reyland ME, Hunter S, Deisher LM, Barzen KA, Quissell DO. Etoposide-induced activation of c-jun N-terminal kinase (JNK) correlates with drug-induced apoptosis in salivary gland acinar cells. Cell Death Differ 1999;6:454-62. (Pubitemid 29245959)
18. Brantley-Finley C, Lyle CS, Du L, Goodwin ME, Hall T, Szwedo D, et al. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 2003;66:459-69. (Pubitemid 36937031)
19. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55-61. (Pubitemid 34297080)
20. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24. (Pubitemid 34462457)
21. Barker CR, Hamlett J, Pennington SR, Burrows F, Lundgren K, Lough R, et al. The topoisomerase II-Hsp90 complex: a new chemotherapeutic target? Int J Cancer 2006;118:2685-93. (Pubitemid 43673345)
22. Ko JC, Ciou SC, Cheng CM, Wang LH, Hong JH, Jheng MY, et al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 2008;29:1448-58.
23. Chuang SM, Wang LH, Hong JH, Lin YW. Induction of Rad51 protein levels by p38 MAPK decreases cytotoxicity and mutagenicity in benzo[a]pyrene-exposed human lung cancer cells. Toxicol Appl Pharmacol 2008;230:290-7.
24. Cheng Y, Chang LW, Tsou TC. Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch Toxicol 2006;80:310-8. (Pubitemid 43725214)
25. Lin YW, Chuang SM, Yang JL. Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anticytotoxicity and anti-mutagenicity. Carcinogenesis 2003;24:53-61.
26. Poulaki V, Iliaki E, Mitsiades N, Mitsiades CS, Paulus YN, Bula DV, et al. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J 2007;21:2113-23. (Pubitemid 47026447)
27. Kurosu T, Takahashi Y, Fukuda T, Koyama T, Miki T, Miura O. p38MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis 2005;10:1111-20. (Pubitemid 41285586)
28. Lomonaco SL, Kahana S, Blass M, Brody Y, Okhrimenko H, Xiang C, et al. Phosphorylation of protein kinase Cdelta on distinct tyrosine residues induces sustained activation of Erk1/2 via down-regulation of MKP-1: role in the apoptotic effect of etoposide. J Biol Chem 2008;283:17731-9.
29. Reno EM, Haughian JM, Jackson TA, Thorne AM, Bradford AP. c-Jun N-terminal kinase regulates apoptosis in endometrial cancer cells. Apoptosis 2009;14:809-20.
30. Andrieux LO, Fautrel A, Bessard A, Guillouzo A, Baffet G, Langouet S. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res 2007;67:2114-23. (Pubitemid 46424230)
31. Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 2004;64:4849-57.
32. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998;273:23419-25. (Pubitemid 28417531)
33. Yan QW, Reed E, Zhong XS, Thornton K, Guo Y, Yu JJ. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 2006;71:761-71. (Pubitemid 43208832)
34. Christmann M, Tomicic MT, Origer J, Aasland D, Kaina B. c-Fos is required for excision repair of UV-light induced DNA lesions by triggering the re-synthesis of XPF. Nucleic Acids Res 2006;34:6530-9. (Pubitemid 46017948)
35. Hayakawa J, Depatie C, Ohmichi M, Mercola D. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 2003;278:20582-92. (Pubitemid 36806356)
36. Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997;272:14041-4. (Pubitemid 27232804)
37. Zhao Q, Barakat BM, Qin S, Ray A, El-Mahdy MA, Wani G, et al. The p38 mitogen-activated protein kinase augments nucleotide excision repair by mediating DDB2 degradation and chromatin relaxation. J Biol Chem 2008;283:32553-61.
38. Ming M, Feng L, Shea CR, Soltani K, Zhao B, Han W, et al. PTEN positively regulates UVB-induced DNA damage repair. Cancer Res 2011;71:5287-95.
39. Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 2007;102:522-38. (Pubitemid 47000605)
40. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10. (Pubitemid 37187270)
41. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006;95:323-48. (Pubitemid 44088424)
42. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7. (Pubitemid 37443877)
43. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005;11:1088-95. (Pubitemid 41486831)
44. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998;79:129-68. (Pubitemid 28380440)
45. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007;13:1625-9. (Pubitemid 46952925)
46. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76. (Pubitemid 37039035)
47. Yao Q, Weigel B, Kersey J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 2007;13:1591-600. (Pubitemid 46450452)